Mencacci Niccolò E, Carecchio Miryam
aDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom bMolecular Neurogenetics Unit cDepartment of Pediatric Neurology, IRCCS Foundation Carlo Besta Neurological Institute dDepartment of Molecular and Translational Medicine, University of Milan Bicocca, Milan, Italy.
Curr Opin Neurol. 2016 Aug;29(4):486-95. doi: 10.1097/WCO.0000000000000352.
Chorea presenting in childhood and adulthood encompasses several neurological disorders, both degenerative and nonprogressive, often with a genetic basis. In this review, we discuss how modern genomic technologies are expanding our knowledge of monogenic choreic syndromes and advancing our insight into the molecular mechanisms responsible for chorea.
A genome-wide association study in Huntington's disease identified genetic disease modifiers involved in controlling DNA repair mechanisms and stability of the HTT trinucleotide repeat expansion. Chorea is the cardinal feature of newly recognized genetic entities, ADCY5 and PDE10A-related choreas, with onset in infancy and childhood. A phenotypic overlap between chorea, ataxia, epilepsy, and neurodevelopmental disorders is becoming increasingly evident.
The differential diagnosis of genetic conditions presenting with chorea has considerably widened, permitting a molecular diagnosis and an improved prognostic definition in an expanding number of cases. The identification of Huntington's disease genetic modifiers and new chorea-causing gene mutations has allowed the initial recognition of converging molecular pathways underlying medium spiny neurons degeneration and dysregulation of normal development and activity of basal ganglia circuits. Signalling downstream of dopamine receptors and control of cAMP levels represent a very promising target for the development of new aetiology-based treatments for chorea and other hyperkinetic disorders.
儿童期和成年期出现的舞蹈症涵盖多种神经系统疾病,包括退行性和非进行性疾病,通常具有遗传基础。在本综述中,我们讨论现代基因组技术如何扩展我们对单基因舞蹈症综合征的认识,并增进我们对舞蹈症发病分子机制的理解。
一项针对亨廷顿舞蹈症的全基因组关联研究确定了参与控制DNA修复机制和HTT三核苷酸重复序列扩增稳定性的遗传疾病修饰因子。舞蹈症是新发现的遗传疾病实体(与ADCY5和PDE10A相关的舞蹈症)的主要特征,发病于婴儿期和儿童期。舞蹈症、共济失调、癫痫和神经发育障碍之间的表型重叠日益明显。
以舞蹈症为表现的遗传疾病的鉴别诊断范围已大幅拓宽,使得越来越多的病例能够进行分子诊断并改善预后定义。亨廷顿舞蹈症遗传修饰因子和新的舞蹈症致病基因突变的鉴定,使我们初步认识到中棘神经元变性以及基底神经节回路正常发育和活动失调背后的共同分子途径。多巴胺受体下游信号传导和cAMP水平的控制是开发基于新病因的舞蹈症及其他运动亢进性疾病治疗方法非常有前景的靶点。